DMRA.US Damora Therapeutics, Inc.
- Market cap
- USD 1.34B
- P/E
- 12.6x
- P/B
- 3.72x
- ROE
- -24.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is DMRA.US undervalued?
Graham numberDMRA.US trades 44.6% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Damora Therapeutics, Inc. fundamental analysis
No fundamental analysis for Damora Therapeutics, Inc. yet.
Damora Therapeutics, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Damora Therapeutics, Inc.
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB…
Full company profileDamora Therapeutics, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Damora Therapeutics, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | - | -111K | -188K | -441K | -490K | -830K | -181K | -34.0K | -457K |
| Operating Income | -12.9M | -39.0M | -33.6M | -52.2M | -61.2M | -36.5M | -16.9M | -211M | -137M |
| EBITDA | -12.9M | -38.9M | -33.4M | -51.3M | -61.1M | -37.5M | -21.2M | -210M | -132M |
| Net Income | -15.9M | -36.5M | -34.8M | -51.8M | -61.6M | -38.3M | -21.4M | -210M | -121M |
| EPS | -16 | -36 | -34 | -51 | -61 | -36 | -19 | -154 | -1.96 |
| Balance Sheet | |||||||||
| Total Assets | 35.1M | 56.6M | 172M | 122M | 73.2M | 38.2M | 17.1M | 261M | 533M |
| Total Liabilities | 4.44M | 8.14M | 6.11M | 4.99M | 11.4M | 5.90M | 2.66M | 20.1M | 36.9M |
| Shareholders' Equity | 30.7M | 48.5M | 165M | 117M | 61.8M | 32.3M | 14.5M | 240M | 496M |
| Cash & Short-term Investments | 31.0M | 11.3M | 164M | 100M | 60.2M | 33.2M | 14.2M | 258M | 528M |
| Total Debt | - | 298K | 915K | 847K | 804K | 249K | 1.43M | 68.0K | 1.10M |
| Cash Flow | |||||||||
| Operating Cash Flow | -13.7M | -19.3M | -38.2M | -52.3M | -42.9M | -36.9M | -18.6M | -6.73M | -79.6M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 223K | 196K | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -13.7M | -19.3M | -38.2M | -52.5M | -43.1M | -36.9M | -18.6M | -6.73M | -79.6M |
| Ratios | |||||||||
| ROE | -51.8% | -75.3% | -21.1% | -44.1% | -99.8% | -118.6% | -148.2% | -87.3% | -24.5% |
| ROA | -45.2% | -64.5% | -20.3% | -42.3% | -84.2% | -100.3% | -125.1% | -80.5% | -22.8% |
| Debt to Equity | - | 0.01x | 0.01x | 0.01x | 0.01x | 0.01x | 0.10x | 0.00x | 0.00x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Damora Therapeutics, Inc. dividends
Damora Therapeutics, Inc. has not paid dividends in the last 8 fiscal years.
Last stock split: 1:25 on Aug 30, 2024.
Who owns Damora Therapeutics, Inc.
- Insiders 10.16%
- Institutions 89.84%
- Public & others 0.00%
- Shares outstanding 61.9M
- Free float 41.6M
Top funds holding DMRA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Growth Company Fund | 1.84M | 2.96% | +0.46% | Aug 2026 |
| iShares Russell 2000 ETF | 1.19M | 1.93% | 0.00% | Oct 2026 |
| Fidelity Small Cap Growth | 834K | 1.35% | 0.00% | Aug 2026 |
| State Street® SPDR® S&P® Biotech ETF | 777K | 1.25% | +2.68% | Oct 2026 |
| JPMorgan Small Cap Growth A | 706K | 1.14% | -0.61% | Sep 2026 |
| Fidelity Small Cap Index | 585K | 0.94% | +0.15% | Aug 2026 |
| Fidelity Growth Company K6 | 540K | 0.87% | +0.48% | Aug 2026 |
| Fidelity Select Health Care | 500K | 0.81% | 0.00% | Aug 2026 |
| Fidelity Series Growth Company | 455K | 0.73% | +0.46% | Aug 2026 |
| Fidelity Select Biotechnology | 455K | 0.73% | 0.00% | Aug 2026 |
| Fidelity Small Cap Growth K6 | 410K | 0.66% | 0.00% | Aug 2026 |
| Fidelity Stock Selector Small Cap | 404K | 0.65% | +0.20% | Aug 2026 |
| JPM Global Healthcare C acc USD | 316K | 0.51% | -26.33% | Sep 2026 |
| Fidelity Series Small Cap Opps | 309K | 0.50% | +0.26% | Aug 2026 |
| iShares Russell 2000 Growth ETF | 307K | 0.50% | -0.38% | Oct 2026 |
| Fidelity Advisor Biotechnology I | 298K | 0.48% | 0.00% | Sep 2026 |
| Fidelity Advisor Health Care I | 280K | 0.45% | 0.00% | Sep 2026 |
| Vanguard Russell 2000 ETF | 274K | 0.44% | -10.65% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 263K | 0.43% | +0.23% | Oct 2026 |
| Fidelity Extended Market Index | 225K | 0.36% | +150.63% | Sep 2026 |
Top institutions holding DMRA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| FMR Inc | 9.23M | 14.96% | +2.07% | Jun 2026 |
| venBio Select Advisor LLC | 3.78M | 6.13% | 0.00% | Jun 2026 |
| BlackRock Inc | 3.16M | 5.12% | +1,321.56% | Jun 2026 |
| Viking Global Investors LP | 2.31M | 3.74% | 0.00% | Jun 2026 |
| Remedium Capital Partners, LLC | 2.05M | 3.31% | 0.00% | Jun 2026 |
| COMMODORE CAPITAL LP | 1.94M | 3.14% | 0.00% | Jun 2026 |
| BRAIDWELL LP | 1.62M | 2.62% | +81.08% | Jun 2026 |
| Bellevue Group AG | 1.62M | 2.62% | -29.55% | Jun 2026 |
| State Street Corp | 1.55M | 2.50% | +740.30% | Jun 2026 |
| Balyasny Asset Management LLC | 1.23M | 1.99% | -15.12% | Jun 2026 |
| Perceptive Advisors LLC | 1.22M | 1.98% | 0.00% | Jun 2026 |
| Wellington Management Company LLP | 1.06M | 1.71% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 965K | 1.56% | +300.36% | Jun 2026 |
| Siren, L.L.C. | 900K | 1.46% | 0.00% | Jun 2026 |
| UBS Group AG | 840K | 1.36% | +423.82% | Jun 2026 |
| Vestal Point Capital LP | 575K | 0.93% | -4.17% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 365K | 0.59% | 0.00% | Jun 2026 |
| Northern Trust Corp | 360K | 0.58% | +825.12% | Jun 2026 |
| The Goldman Sachs Group Inc | 339K | 0.55% | +284.19% | Jun 2026 |
| Ikarian Capital, LLC | 336K | 0.54% | 0.00% | Jun 2026 |
Damora Therapeutics, Inc. company profile
- Company name
- Damora Therapeutics, Inc.
- Ticker
- DMRA.US
- ISIN
- KYG2646Y1044
- Exchange
- USA Stocks
- Listed since
- Mar 10, 2026
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 7
- Fiscal year end
- December
- Address
- Building 23, Waltham, MA, United States, 02453
- Phone
- 781 281 9020
- Website
- damoratx.com
About Damora Therapeutics, Inc.
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
Damora Therapeutics, Inc. management
8- Mr. Garrett Winslow Esq.Senior VP, General Counsel & Corporate Secretary · born 1979
- Ms. Jennifer A. Jarrett M.B.A.CEO, President & Director · born 1971
- Mr. Ulf J. Nilsson Ph.D.Co-Founder
- Dr. Hakon Leffler M.D., Ph.D.Co-Founder
- Prof. Tariq Sethi B.Sc., FRCP, M.A., M.D., Ph.D.Co-Founder
- Mr. Brian Burkavage CPASenior VP of Finance, Principal Financial & Accounting Officer · born 1983
- Mr. Sherwin SattarzadehChief Operating Officer · born 1979
- Dr. Becker Hewes M.D.Chief Medical Officer · born 1966